Matches in SemOpenAlex for { <https://semopenalex.org/work/W2060809570> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W2060809570 endingPage "68" @default.
- W2060809570 startingPage "66" @default.
- W2060809570 abstract "The role of microbiota in biliary atresia (BA) remains unclear. The aim of our study was to assess efficacy and safety of LGG treatment in children with BA after HPE with special focus on bacterial cholangitis (BCH) and quantitative assessment of the gut microbiota composition and metabolism.We performed double-blind placebo controlled trial with patients randomized into treatment group who received LGG (n = 14) and placebo (n = 16). The gut microbiota and short-chain fatty acids (SCFA) were assessed at baseline and after 6 months of treatment. Clinical and laboratory parameters including episodes of bacterial cholangitis (BCH) were collected during the study period and after 2-year follow-up. Additionally, stool composition of BA patients was compared with healthy age-matched control group.There were lower concentration of SCFA in children with BA compared to control group and significant increase in the number of Enterococcus bacteria. After 6 months of treatment, neither laboratory parameters nor gut microbiota composition differed between LGG group and placebo. PP analysis results were similar to ITT analysis, no significant differences between study and control group. Overall, there were 11 (36%) patients who developed at least one episode of bacterial cholangitis; 3 (21%) in the LGG group compared to 8 (50%) placebo group (p = 0.14). Bacterial cultures were positive in 22% of cases and recurrence after the first episode was observed in 27% of patients. The level of total bilirubin decreased below 2 mg/dl after 6 months of the study in 6 (42.8%) patients in the LGG group and in 8 (50%) patients in the placebo group (p = 0.73). During 2-year follow-up 6 out of 14 patients (42.8%) in the LGG group and 11 out of 16 placebo patients (68.7%) underwent liver transplantation (p = 0.27).Patients with BA present with specific microbiota profiles and decreased SCFA what gives opportunities to implement novel therapeutic options based on modulation of microbiota. Whether LGG is an effective therapy needs to be studied in a larger group with similar outcome parameters." @default.
- W2060809570 created "2016-06-24" @default.
- W2060809570 creator A5000239890 @default.
- W2060809570 creator A5005689729 @default.
- W2060809570 creator A5011015801 @default.
- W2060809570 creator A5021382604 @default.
- W2060809570 creator A5026741416 @default.
- W2060809570 creator A5028907409 @default.
- W2060809570 creator A5053976382 @default.
- W2060809570 date "2011-02-01" @default.
- W2060809570 modified "2023-09-27" @default.
- W2060809570 title "Une volumineuse masse hépatique" @default.
- W2060809570 cites W2037635069 @default.
- W2060809570 cites W2064732137 @default.
- W2060809570 cites W2103996871 @default.
- W2060809570 cites W2115588068 @default.
- W2060809570 cites W2401234890 @default.
- W2060809570 cites W2428256390 @default.
- W2060809570 doi "https://doi.org/10.1016/j.annpat.2010.07.006" @default.
- W2060809570 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21349394" @default.
- W2060809570 hasPublicationYear "2011" @default.
- W2060809570 type Work @default.
- W2060809570 sameAs 2060809570 @default.
- W2060809570 citedByCount "1" @default.
- W2060809570 countsByYear W20608095702016 @default.
- W2060809570 crossrefType "journal-article" @default.
- W2060809570 hasAuthorship W2060809570A5000239890 @default.
- W2060809570 hasAuthorship W2060809570A5005689729 @default.
- W2060809570 hasAuthorship W2060809570A5011015801 @default.
- W2060809570 hasAuthorship W2060809570A5021382604 @default.
- W2060809570 hasAuthorship W2060809570A5026741416 @default.
- W2060809570 hasAuthorship W2060809570A5028907409 @default.
- W2060809570 hasAuthorship W2060809570A5053976382 @default.
- W2060809570 hasConcept C126322002 @default.
- W2060809570 hasConcept C142724271 @default.
- W2060809570 hasConcept C168563851 @default.
- W2060809570 hasConcept C203014093 @default.
- W2060809570 hasConcept C204787440 @default.
- W2060809570 hasConcept C27081682 @default.
- W2060809570 hasConcept C2780965833 @default.
- W2060809570 hasConcept C535046627 @default.
- W2060809570 hasConcept C539455810 @default.
- W2060809570 hasConcept C71924100 @default.
- W2060809570 hasConcept C90924648 @default.
- W2060809570 hasConceptScore W2060809570C126322002 @default.
- W2060809570 hasConceptScore W2060809570C142724271 @default.
- W2060809570 hasConceptScore W2060809570C168563851 @default.
- W2060809570 hasConceptScore W2060809570C203014093 @default.
- W2060809570 hasConceptScore W2060809570C204787440 @default.
- W2060809570 hasConceptScore W2060809570C27081682 @default.
- W2060809570 hasConceptScore W2060809570C2780965833 @default.
- W2060809570 hasConceptScore W2060809570C535046627 @default.
- W2060809570 hasConceptScore W2060809570C539455810 @default.
- W2060809570 hasConceptScore W2060809570C71924100 @default.
- W2060809570 hasConceptScore W2060809570C90924648 @default.
- W2060809570 hasIssue "1" @default.
- W2060809570 hasLocation W20608095701 @default.
- W2060809570 hasLocation W20608095702 @default.
- W2060809570 hasOpenAccess W2060809570 @default.
- W2060809570 hasPrimaryLocation W20608095701 @default.
- W2060809570 hasRelatedWork W2028963438 @default.
- W2060809570 hasRelatedWork W2099482902 @default.
- W2060809570 hasRelatedWork W2129764344 @default.
- W2060809570 hasRelatedWork W2158225596 @default.
- W2060809570 hasRelatedWork W2167033828 @default.
- W2060809570 hasRelatedWork W2369933494 @default.
- W2060809570 hasRelatedWork W2383192665 @default.
- W2060809570 hasRelatedWork W4233016836 @default.
- W2060809570 hasRelatedWork W4256514411 @default.
- W2060809570 hasRelatedWork W4360603369 @default.
- W2060809570 hasVolume "31" @default.
- W2060809570 isParatext "false" @default.
- W2060809570 isRetracted "false" @default.
- W2060809570 magId "2060809570" @default.
- W2060809570 workType "article" @default.